SCHEMBL23907332

SCHEMBL23907332

CCOC(=O)C1C(=O)CCN(C(C)(C)C)C1=O

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
GAA P10253 3/20 0.37
PKM P14618 1/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 4/20 0.37
HSD17B10 Q99714 2/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
FKBP1A P62942 2/20 0.35
TLR4 O00206 1/20 0.35
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22207029 0.98 MAPT (0.50) MAPTGAAPKMHTTALDH1A1
SCHEMBL22216413 0.88 MAPT (0.43) MAPTGAAPKMHTTALDH1A1
SCHEMBL22216178 0.86 MAPT (0.52) MAPTGAAPKMHTTALDH1A1
SCHEMBL1303947 0.80 ALDH1A1 (0.39) MAPTGAAHTTALDH1A1HSD17B10
SCHEMBL22216464 0.79 MAPT (0.40) MAPTGAAPKMHTTALDH1A1
SCHEMBL22338336 0.78 MAPT (0.39) MAPTGAAPKMHTTALDH1A1
SCHEMBL22323036 0.78 MAPT (0.39) MAPTGAAPKMHTTALDH1A1
SCHEMBL3367604 0.78 ALDH1A1 (0.39) MAPTGAAPKMALDH1A1HSD17B10
SCHEMBL22323003 0.76 ALDH1A1 (0.40) MAPTPKMALDH1A1TLR4MEN1
SCHEMBL22207271 0.76 MAPT (0.37) MAPTGAAALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371432-B2 Haloallylamine compounds and application thereof TRANSTHERA SCIENCES (NANJING), INC. (CN) 2025-07-29 US disclosed
EP-3892621-B1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2024-09-18 EP disclosed
CN-111434662-B Haloallylamine compound and application thereof 药捷安康(南京)科技股份有限公司 2023-01-10 CN disclosed
US-20220081439-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF TransThera Sciences (Nanjing), Inc (CN) 2022-03-17 US disclosed
EP-3892621-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-10-13 EP disclosed
EP-3892621-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371432-B2 Haloallylamine compounds and application thereof ADRA1D, ADRA1A, VAPA MAPT 398/4885GAA 2675/4885PKM 2499/4885
US-20220081439-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF ADRA1D, ADRA1A, VAPA MAPT 398/4885GAA 2675/4885PKM 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.